My Basket
You're new here! Welcome, please feel free to browse our store.

Email Address
Password
Please fill in your email address below to join our newsletter mailing list.
You Are Here: Home - M - Q - Prascend (Pergolide) 1mg tabs (priced per tablet)
Prascend (Pergolide) 1mg tabs (priced per tablet)
Prascend (Pergolide) 1mg tabs (priced per tablet)
New Product
Prescription Required Prescription Only
Our Price: £0.97
Quantity:
Product Options

Presentation
Pink, rectangular scored tablet, engraved on one side with the Boehringer Ingelheim logo and the letters "PRD. The tablets can be divided into equal halves. Each tablet contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg).
 
Uses
Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction, PPID (Equine Cushings Disease).
 
Dosage and administration
The product should be administered orally, once daily. To facilitate administration, the required daily dose should be placed in a small amount of water and/or mixed with molasses or other sweetener and agitated until dissolved. In this case, the dissolved tablets should be administered with a syringe. The whole amount should be administered immediately. Tablets should not be crushed.
Starting dose
The starting dose is 2 g pergolide/kg body weight. Studies from the published literature cite the most common, average dose as 2 g pergolide/kg with a range from 0.6 10 g pergolide/kg (0.25 mg 5 mg total daily dose per horse). The starting dose (2 g pergolide/kg) should then be titrated according to the individual response as determined by monitoring (see below). Starting doses are recommended as follows:
Horse Body Weight
Number of Tablets
Starting Dose
Dosage Range
200 - 400 kg
0.5 mg
1.3 - 2.5 g/kg
400 - 600 kg
1
1.0 mg
1.7 - 2.5 g/kg
601 - 850 kg
1
1.5 mg
1.8 - 2.5 g/kg
851 - 1000 kg
2
2.0 mg
2.0 - 2.4 g/kg
Life long treatment is anticipated for this disease. Most horses respond to therapy and are stabilised at an average dose of 2 g pergolide/kg body weight. Clinical improvement with pergolide is expected within 6 to 12 weeks. Horses may respond clinically at lower or varying doses; it is therefore recommended to titrate to the lowest effective dose per individual based on response to therapy, whether it is effectiveness or signs of intolerance. Some horses may require doses as high as 10 g pergolide/kg body weight per day. In these rare situations, appropriate additional monitoring is advised.
Monitoring and dose titration
Following initial diagnosis, repeat endocrinologic testing for dose titration and monitoring of treatment at intervals of 4 to 6 weeks until stabilisation or improvement of clinical signs and/or diagnostic testing occurs. Clinical signs are: hirsutism, polyuria, polydipsia, muscle wasting, abnormal fat distribution, chronic infections, laminitis, sweating, etc. The approach to treatment is the dose titration to the lowest effective dose per individual, based on response to therapy, whether it is effectiveness or signs of intolerance. Depending on the severity of the disease, time to treatment response may vary among individuals. If clinical signs or the diagnostic testing have not yet improved at the first 4 to 6 week interval, the total daily dose may be increased by 0.5 mg. In case clinical signs have improved but are not yet normalised, the veterinarian may decide to titrate or not to titrate the dose, considering the individuals response/tolerance to the dose. In case clinical signs are not adequately controlled (clinical evaluation and/or diagnostic testing) it is recommended to increase the total daily dose by 0.5 mg increments every 4 to 6 weeks until stabilisation occurs and if the drug is tolerated at that dose. If signs of dose intolerance develop, treatment should be stopped for 2-3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2-4 weeks. If a dose is missed, the next scheduled dose should be administered as prescribed. Following stabilisation, regular clinical assessment and diagnostic testing should be performed every 6 months to monitor treatment and dose. Where there is no apparent response to treatment, the diagnosis should be re-evaluated.
 
Contra-indications, warnings, etc
Do not use in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.
Do not use in horses less than 2 years of age.
Appropriate endocrinologic laboratory tests should be conducted as well as evaluation of clinical signs in order to establish a diagnosis of PPID. As the majority of cases of PPID are diagnosed in aged horses, other pathological processes are frequently present. Potential adverse reactions in horses include inappetence, transient anorexia and lethargy, mild central nervous system signs (e.g. mild depression and mild ataxia), diarrhoea and colic. If signs of dose intolerance develop, treatment should be stopped for 2-3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2-4 weeks.
Use with caution if the product is co-administered with other drugs known to affect protein binding. Do not administer concurrently with dopamine antagonists, such as neuroleptics (phenothiazines), domperidone, or metoclopramide, as these agents may reduce the effectiveness of pergolide. There is no clinical experience with massive overdose.
Use during pregnancy and lactation
Pregnancy: use only according to the benefit/ risk assessment by the responsible veterinarian. The safety has not been demonstrated in pregnant mares. Laboratory studies in mice and rabbits have not produced any evidence of teratogenic effects. Reduced fertility was seen in mice at a dose of 5.6 mg/kg body weight per day.
Lactation: the use is not recommended in lactating horses, in which the safety of this product has not been demonstrated. In mice, reduced body weights and survival rates in the progeny were attributed to the pharmacological inhibition of prolactin secretion resulting in lactation failure.
Withdrawal period
Not authorised for use in horses intended for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation. Not authorised for use in mares producing milk for human consumption.
User precautions
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. People with known hypersensitivity to pergolide or other ergot derivatives should avoid contact with the veterinary medicinal product and should not administer it. Splitting or crushing pergolide tablets may cause eye irritation, an irritating smell, or headache. Minimise exposure risks when splitting tablets. Tablets should not be crushed. In case of contact with skin, wash exposed skin with water. In the event of pergolide exposure to the eye, flush the affected eye immediately with water and get medical advice. For nasal irritation, move to fresh air and seek for medical attention if breathing difficulty develops. Pregnant or lactating women should wear gloves when administering the product.
 
Pharmaceutical precautions
Any unused product or waste materials should be disposed of in accordance with local requirements. For animal treatment only. Keep out of reach and sight of children. Do not store above 25C. Store the blister in the original carton.
 
Packaging Quantities
Package sizes: 60, 100 or 160 tablets. Not all pack sizes may be marketed.
 
Further information
Pharmacodynamic properties
Pergolide is a synthetic ergot derivative and is a potent, long-acting dopamine receptor agonist. Both in vitro and in vivo pharmacological studies have demonstrated the activity of pergolide as a selective dopamine agonist with little or no effect on norepinephrine, epinephrine or serotonin pathways at therapeutic doses. As with other dopamine agonists, pergolide inhibits the release of prolactin. In horses with Pituitary Pars Intermedia Dysfunction (PPID) pergolide is believed to exert its therapeutic effect by stimulating dopamine receptors. Further, in horses with PPID, pergolide has been shown to decrease the plasma levels of ACTH, MSH and other pro-opiomelanocortin peptides.
Pharmacokinetic particulars
Available pharmacokinetic information in the horse is limited to two small studies using oral doses of doses of 2 g/kg and 10 g/kg. These studies demonstrated that pergolide is rapidly absorbed with a short time to peak concentration.
Peak concentrations (Cmax) following an exaggerated dose of 10 g/kg were low and variable with a mean of ~ 4 ng/mL and a mean terminal half life (T1/2) of ~ 6 hours. The median time of peak concentration (Tmax) was ~0.4 hrs and the area under the curve (AUC) was ~ 14 ng*h/ml. The terminal half life in this study was much shorter than reported in humans. This is likely due to the sensitivity of the analytical assay in this study which did not allow for complete elucidation of the concentration - time profile. Therefore the rapid estimated rate of elimination in this study may not be a true reflection of the elimination phase.
In a second study using a more sensitive analytical assay, plasma concentrations following the use dose of 2 g/kg were very low and variable with peak concentrations ranging from 138 to 551 pg/ml. The peak concentrations occurred at 1.25 +/- 0.5 hr (Tmax). Plasma concentrations from most horses were quantifiable for only 6 hours post dose. However, one horse had quantifiable concentrations through 24 hours. Terminal half-lives were not calculated as there was incomplete elucidation of the plasma concentration-time curve for most horses. Pergolide mesylate is approximately 90 % associated with plasma proteins in humans and laboratory animals.

Customer Reviews

There are currently no reviews for this product. Be the first to review by clicking below!


Review this product...
People who purchased this also purchased...
Danilon Equidos Sachets
Presentation Sachets containing 10 g of yellow, odourless granules for top dressing. Each sachet contains 1.5 g of Suxibuzone (microencapsulate...
Our Price: £44.39

Telephone Payment Fee
New Product
Our Price: £1.00

Frontline Spray ( 500mls )
Presentation Cutaneous spray solution containing 0.25% w/v fipronil, a member of the phenylpyrazole group of compounds, for external spray appl...
Our Price: £36.70

Equipalazone Sachets (100 sachets)
Presentation 1 sachet contains: Active substance: Micro-encapsulated Phenylbutazone 1 g Excipients: Acacia, gelatin, silicon dioxid...
Our Price: £65.88

Frontline Spot On Large Dog 3 pack ( 20kg - 40kg )
Presentation Spot-on solution containing 10% w/v fipronil. Presented in plastic pipettes, each containing 0.67 ml (67 mg fipronil), 1...
Our Price: £16.94

Frontline Spot On Medium Dog 3 pack ( 10kg - 20kg )
Presentation Spot-on solution containing 10% w/v fipronil. Presented in plastic pipettes, each containing 0.67 ml (67 mg fipronil), 1.34 ml (13...
Our Price: £15.24

Drontal Cat Tabs (priced per tablet)
Broad spectrum cat wormer. Treats roundworm and tapeworm.
Our Price: £1.62

Seraquin Tabs 2g (pack of 60)
New Product
Recommended Product
Special Offer
Seraquin is a nutritional supplement for the support of normal joint function in dogs. How to use Seraquin Seraquin is very palatable to ...
Our Price: £16.98

Filta Bac 120g
New Product
Filtabac is a protective barrier film covering cream for minor wounds, cuts or abrasions, with the added benefit of sun protection.   F...
Our Price: £7.37

This site and all contents are ©2008 Vet Meds Online
Email: orders@vetmedsonline.co.uk
VAT Reg No. 153 2895 96